Pascolizumab

CAS No. 331243-22-2

Pascolizumab( —— )

Catalog No. M36890 CAS No. 331243-22-2

Pascolizumab (SB-240683) is a humanized monoclonal antibody targeting IL-4, exhibiting asthmatic effects and useful for studying allergic rhinitis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 560 In Stock
10MG 911 In Stock
25MG 1349 In Stock
50MG 1786 In Stock
100MG 2409 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Pascolizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Pascolizumab (SB-240683) is a humanized monoclonal antibody targeting IL-4, exhibiting asthmatic effects and useful for studying allergic rhinitis.
  • Description
    Pascolizumab (SB-240683) is a humanized anti-IL-4 monoclonal antibody. Pascolizumab has the potential for the research of asthma.
  • In Vitro
    Cell Proliferation Assay Cell Line:human or monkey T cells Concentration:0-10000 pM Incubation Time:3 days Result:Inhibited the response of human and monkey T cells to recombinant monkey IL-4 (2 ng/ml) with IC50 values of 268 pM and 587 pM, respectively.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    IL Receptor
  • Recptor
    IL Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    331243-22-2
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Hart TK, et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol. 2002 Oct;130(1):93-100.?
molnova catalog
related products
  • IL-4-inhibitor-1

    IL-4 inhibitor is an inhibitor of IL-4.1It binds to IL-4 with a Kdvalue of 1.8 μM and inhibits IL-4 activity in a cell-based reporter assay (EC50= 1.81 μM).

  • Daclizumab

    Daclizumab (Zenapax) is a humanized monoclonal antibody that specifically inhibits the alpha subunit of IL-2R-HA.

  • Mepolizumab

    Mepolizumab is a humanized monoclonal antibody neutralizing IL-5. Mepolizumab can be used in studies about severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.